JPMorgan Starts C4 Therapeutics (CCCC) at Overweight

October 9, 2026 3:22 AM EDT Send to a Friend
JPMorgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ: CCCC) with a Overweight rating and a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login